In vivo efficacy study of BMS-986365 and enzalutamide in mCRPC PDX models

This study is aimed to explore in vivo trascriptional response of BMS-986365 and enzalutamide in mCRPC PDX models CTG-2441 and CTG-2440 which were derived from bone metastases of the same patient following progression on ADT or ADT plus abiraterone treatments, respectively. Overall design: Male NOG immunocompromised mice were implanted subcutaneously into the left flank with tumor fragments from CTG-2441 and CTG02440 prostate cancer models. Mice were dose with 7 days of QD dosing by oral gavage of vehicle, BMS-986365 (60 mg/kg), and ENZ (50 mg/kg) and carried out at Champions Oncology (Rockville, MD, USA). At 6 hours post final dose, tumor samples were collected and RNA-seq was performed.